Osteoporosis Screening in the Reconstructive Urology & Urogynecology Patient
Postmenopausal women constitute the majority of the reconstructive urology and urogynecology patient panel, and many carry iatrogenic bone-loss risk from treatments central to this specialty — GnRH agonists used for preoperative hormonal priming or endometriosis management, aromatase inhibitors prescribed to breast cancer survivors, and prolonged glucocorticoids for IC/BPS with Hunner lesions.[1] Vertebral fractures alter pelvic geometry, worsen incontinence and prolapse biomechanics, and complicate operative positioning; hip fractures in this population carry substantial morbidity and mortality. The 2025 USPSTF reaffirmed a Grade B recommendation for dual-energy x-ray absorptiometry (DXA) screening in all postmenopausal women aged ≥ 65 years, and in younger postmenopausal women with elevated fracture risk — making osteoporosis screening a core component of the comprehensive preventative-care visit.[2]
Who to Screen
Universal threshold: ≥ 65 years
DXA screening is recommended for all postmenopausal women aged ≥ 65 years, without requiring additional risk factor assessment.[2]
Younger postmenopausal women (< 65 years)
A practical two-step approach applies to younger postmenopausal women:
- Assess clinical risk using a validated tool such as FRAX (frax.shef.ac.uk) — no DXA is needed at this step.
- Proceed to DXA if the 10-year FRAX probability of a major osteoporotic fracture exceeds approximately 9.3% — the threshold equivalent to a 65-year-old white woman without additional risk factors.[3]
Risk factors warranting earlier screening
| Category | Examples |
|---|---|
| GU / gynecologic treatments | GnRH agonists (preoperative priming, endometriosis, fibroids), aromatase inhibitors (breast cancer survivors), prolonged estrogen deprivation |
| Other medications | Glucocorticoids ≥ 5 mg/day for ≥ 3 months, anticonvulsants, medroxyprogesterone acetate |
| Anthropometric | Low body weight (<127 lb / 57.6 kg), BMI <20 kg/m² |
| Lifestyle | Current smoking, alcohol >3 drinks/day |
| Medical conditions | Rheumatoid arthritis, type 1 or 2 diabetes, hyperparathyroidism, celiac disease / malabsorption syndromes |
| Family history | Parental history of hip fracture |
| Reproductive | Premature menopause (<45 years), prolonged amenorrhea |
Six months of GnRH agonist therapy (e.g., leuprolide for preoperative uterine or fibroid management) reduces lumbar spine BMD by 4–8%. For courses exceeding 3–6 months, bone-protective co-therapy with add-back estrogen-progestin or a bisphosphonate should be considered. Document baseline and post-treatment DXA accordingly.
Diagnosis
Osteoporosis is diagnosed when any of the following criteria are met:[1][7]
- DXA T score ≤ −2.5 at the lumbar spine, total hip, or femoral neck
- Low-trauma (fragility) fracture at the hip, vertebra, or other site — regardless of T score
Osteopenia is defined as a T score between −1.0 and −2.5; this range requires FRAX integration to determine treatment need.
T scores are compared to a young-adult reference population (female, age 20–29); Z scores compare to age-matched peers and are preferred in premenopausal women and men.
FRAX and Risk Stratification
The FRAX calculator integrates age, sex, BMI, and clinical risk factors to estimate 10-year probability of hip fracture and major osteoporotic fracture. It can be run with or without BMD input; adding femoral neck T score improves predictive accuracy.
Pharmacologic treatment is recommended for patients meeting any of the following thresholds:[1][7]
| Criterion | Threshold |
|---|---|
| Fragility fracture | Hip or vertebral fracture — treat regardless of T score |
| DXA T score | ≤ −2.5 at femoral neck, total hip, or lumbar spine |
| Osteopenia + FRAX | T score −1.0 to −2.5 and 10-year hip fracture risk ≥ 3% or major osteoporotic fracture risk ≥ 20% |
Risk is then stratified into high vs very high risk to guide agent selection (see Treatment below).
Guideline Comparison
| Society | Universal Threshold | Early Screening | Interval |
|---|---|---|---|
| USPSTF 2025 [2] | Age ≥ 65 (Grade B) | <65 if FRAX ≥ 9.3% | Not specified |
| ACOG [4] | Age ≥ 65 | <65 with risk factors | Every 2 yr if borderline; annual for chronic glucocorticoids |
| ACR [5] | Age ≥ 65 | <65 with risk factors | Not specified |
| BHOF / NOF [6] | Age ≥ 65 | <65 with risk factors | Every 2 yr for average-risk women ≥ 65 |
Screening Interval
The optimal rescreening interval is not firmly established by RCT evidence. Practical guidance:[4][6]
- Normal or mild osteopenia (T score > −1.5): rescreening in 10–15 years is reasonable; <10% of these patients will develop osteoporosis within 15 years.
- Moderate osteopenia (T score −1.5 to −2.0): rescreen in 3–5 years.
- Borderline osteopenia (T score −2.0 to −2.5): rescreen in 1–2 years.
- Active glucocorticoid use: annual DXA per ACOG.
- GnRH agonist therapy: obtain baseline DXA before starting; recheck at 12–18 months if ongoing.
Treatment Overview
Full pharmacologic management is outside the scope of this article; the following framework supports risk stratification at the preventative-care visit.
High risk (T ≤ −2.5 or FRAX above thresholds, no prior fragility fracture)
First-line agents are antiresorptives:[1][7]
- Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) — first-line for most; low cost, extensive safety data.
- IV zoledronic acid 5 mg annually — preferred when adherence or GI tolerability is a concern.
- Denosumab 60 mg SC every 6 months — option for renal insufficiency; requires continuous therapy (rebound vertebral fractures on discontinuation).
- Raloxifene (SERM) — modest vertebral benefit, no hip benefit; appropriate in younger postmenopausal women with breast cancer risk.
Very high risk (prior hip or vertebral fragility fracture, or T ≤ −2.5 with FRAX probability well above threshold)
Anabolic agents are preferred first-line:[1]
- Teriparatide (PTH 1-34) 20 µg SC daily × 2 years — reduces vertebral fractures ~65%.
- Romosozumab (anti-sclerostin) 210 mg SC monthly × 12 months — dual anabolic and antiresorptive; avoid in patients with recent MI or stroke.
- Follow with antiresorptive therapy after anabolic course to consolidate gains.
Calcium and vitamin D
Calcium 1,000–1,200 mg/day (dietary preferred over supplemental) and vitamin D 600–800 IU/day are adjuncts for all patients on pharmacologic therapy. Excess supplemental calcium (>1,000 mg/day from supplements) has been associated with cardiovascular risk in some cohorts.
GU-Specific Considerations
- Preoperative hormonal priming: Short-course vaginal estrogen does not meaningfully affect systemic BMD; systemic GnRH agonist priming for ≥ 3 months warrants baseline DXA and bone-protective co-therapy.
- Pelvic floor biomechanics: Vertebral compression fractures increase lumbar lordosis and alter the orientation of the levator plate, potentially worsening POP and stress urinary incontinence. Fall-prevention and balance programs (relevant to both hip fracture prevention and incontinence management) should be included in the care plan.
- Breast cancer survivors on aromatase inhibitors: AIs reduce estrogen to near-undetectable levels and accelerate bone loss (1–3% per year); baseline and annual DXA plus bisphosphonate or denosumab co-therapy is recommended per ASCO / NCCN guidelines.
- Chronic glucocorticoid use (IC/BPS with Hunner lesions, transplant recipients): ACOG recommends annual DXA for any patient on chronic glucocorticoids; threshold for treatment may be lowered to T ≤ −1.5 in this group per BHOF guidance.
References
1. Walker MD, Shane E. "Postmenopausal Osteoporosis." N Engl J Med. 2023;389(21):1979–1991. doi:10.1056/NEJMcp2307353
2. US Preventive Services Task Force, Nicholson WK, Silverstein M, et al. "Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement." JAMA. 2025;333(6):498–508. doi:10.1001/jama.2024.27154
3. Curry SJ, Krist AH, Owens DK, et al. "Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement." JAMA. 2018;319(24):2521–2531. doi:10.1001/jama.2018.7498
4. White L. "Osteoporosis Prevention, Screening, and Diagnosis: ACOG Recommendations." Am Fam Physician. 2022;106(5):587–588.
5. Expert Panel on Musculoskeletal Imaging, Yu JS, Krishna NG, et al. "ACR Appropriateness Criteria® Osteoporosis and Bone Mineral Density: 2022 Update." J Am Coll Radiol. 2022;19(11S):S417–S432. doi:10.1016/j.jacr.2022.09.007
6. Plesa M, Wong A, Katsaggelos E. "Health Maintenance in Postmenopausal Women." Am Fam Physician. 2025;111(5):407–418.
7. Morin SN, Leslie WD, Schousboe JT. "Osteoporosis." JAMA. 2025;334(10):894–907. doi:10.1001/jama.2025.6003